Exhibit 99.1

          VaxGen and EndoBiologics Form Collaboration to Pursue Early
                    Stage Research for Meningitis B Vaccine

      BRISBANE, Calif. and MISSOULA, Mont. - May 4, 2005 - VaxGen, Inc. (Pink
Sheets: VXGN.PK) and EndoBiologics International Corp. announced today that they
have formed a collaboration to pursue research of a vaccine against Meningitis
serogroup B, using technology developed by EndoBiologics. VaxGen intends to fund
proof-of-concept studies during the next 12 months and has an exclusive option
to continue product development if the studies yield promising results.

Meningitis B (Neisseria meningitidis serogroup B) is a life-threatening
bacterial infection most common among young children. The disease is nearly
always fatal if left untreated and 10-15% fatal even if treated with
antibiotics. Of those who recover from the disease, 10-20% experience permanent
hearing loss, mental retardation or loss of limbs. There is no licensed vaccine
that has shown protection against a wide range of Meningitis B strains.

"A safe and effective Meningitis B vaccine would provide a major advance in
improving the health of our children," said Lance K. Gordon, Ph.D., VaxGen's
President and CEO. "A great deal of work remains to be done and there is no
assurance of success, but having carefully evaluated various approaches to
developing a Meningitis B vaccine, VaxGen believes that EndoBiologics has
developed a promising technology. If this approach ultimately results in a
vaccine approved for commercial use, we believe it would be appropriate for
routine pediatric immunization."

The initial proof-of-concept phase will be undertaken jointly by EndoBiologics
and VaxGen, with VaxGen providing research funding to EndoBiologics and
conducting pre-clinical testing of the vaccine candidate.

If VaxGen exercises its option to continue developing the vaccine candidate
after the proof-of-concept studies, the company would provide milestone payments
and additional research funding to EndoBiologics. VaxGen also would provide
EndoBiologics with royalty and additional milestone payments upon regulatory
approval and commercial sale, if those events are forthcoming.

"VaxGen's long-standing interest in and understanding of Meningitis B, coupled
with their experience in product development and manufacturing, made them the
ideal partner for us," said Gary Gustafson, Ph.D., EndoBiologics' President and
CEO. "EndoBiologics believes it has developed a novel and promising technology,
and we are pleased to be working with VaxGen to determine if we can bring it to
the next stage of development."

EndoBiologics' production method uses the organism Dictyostelium discoideum as a
biological mechanism for producing a potential vaccine antigen from
lipooligosaccharide (LOS). LOS is a carbohydrate structure on the surface of the
Meningitis B bacteria. Dictyostelium uses the


Meningitis B bacterium as a food source and produces enzymes that
naturally detoxify the bacterial LOS molecule. The detoxified LOS is then
conjugated, or joined, to a carrier protein using EndoBiologics' proprietary
chemistry to create the vaccine candidate.

During natural infection with Meningitis B or after vaccination with other
vaccine compositions containing LOS, antibodies to LOS are readily detected.
Additionally, at least one monoclonal antibody to a conserved part of LOS has
been shown to protect in a pre-clinical model. Therefore, VaxGen and
EndoBiologics believe that a vaccine that can elicit a robust response to
conserved portions of LOS represents an attractive approach to developing a
product to prevent Neisseria meningitidis infection and disease. (See Vermont et
al. Recent developments in vaccines to prevent meningococcal serogroup B
infections. Current Opinion in Molecular Therapeutics 2003 5(1): 33-38.)

A barrier to using LOS as a vaccine antigen has been the difficulty in
detoxifying this carbohydrate while preserving portions of the antigen essential
to producing a useful vaccine. VaxGen and EndoBiologics believe that
EndoBiologics' production method could alleviate this concern by using a
biological, rather than chemical, means for detoxifying the antigen, thus
potentially preserving important regions thought to be involved in the induction
of protective antibodies. Conjugation of this detoxified LOS to an immunogenic
protein carrier may result in a safe and effective vaccine.

About VaxGen

VaxGen, Inc. is a biopharmaceutical company engaged in the development,
manufacture and commercialization of biologic products for the prevention and
treatment of human infectious disease. Based in Brisbane, Calif., the company is
developing vaccines against anthrax, smallpox and Meningitis B. In November
2004, the U.S. government awarded VaxGen an $877.5 million contract to provide
75 million doses of the company's recombinant anthrax vaccine for civilian
biodefense. VaxGen is also the single largest shareholder in Celltrion, Inc., a
contract manufacturing organization established in South Korea for the
production of biopharmaceutical products grown in mammalian cell culture. For
more information, please visit the company's web site at: www.vaxgen.com.

About EndoBiologics

EndoBiologics is a privately held biotechnology company based in Missoula,
Montana. In addition to its work on a Meningitis B vaccine, the company has a
cooperative research and development agreement (CRADA) with the Walter Reed Army
Institute of Research and grants from the Department of Defense for the
development of vaccines to protect U.S. military troops against bacterial
dysentery.

Note: This press release contains "forward-looking statements" within the
meaning of the federal securities laws. These forward-looking statements include
without limitation, statements regarding the ultimate safety and efficacy of a
vaccine for Meningitis serogroup B; the timing and progress of research and
development efforts of a vaccine candidate against


Meningitis serogroup B; and the timing, progress and likelihood of a
vaccine candidate for Meningitis serogroup B receiving the necessary approvals
for licensure from the U.S. Food and Drug Administration. These statements are
subject to risks and uncertainties that could cause actual results and events to
differ materially from those anticipated. Reference should be made to Section 8
of the company's Form 8-K filed on March 31, 2005, under the heading "Risk
Factors" for a more detailed description of such risks. Readers are cautioned
not to place undue reliance on these forward-looking statements that speak only
as of the date of this release. VaxGen undertakes no obligation to update
publicly any forward-looking statements to reflect new information, events, or
circumstances after the date of this release except as required by law.

Contacts:

VaxGen, Inc.
Lance Ignon
Vice President, Corporate Affairs
Paul Laland
Vice President, Corporate and Financial Communications
(650) 624-1041

EndoBiologics International Corporation
Gary Gustafson
President and CEO
(406) 543-6322